Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CPS1 | P31327 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420671 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KMT2ACPS1MAOBPOLB | |
| SCHEMBL30628292 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KMT2ACPS1MAOBPOLB | |
| SCHEMBL8476474 | 0.86 | ALDH1A1 (0.71) | ALDH1A1KMT2AKAT6APARP10FFAR4 | |
| SCHEMBL6305234 | 0.84 | PARP10 (0.56) | ALDH1A1KMT2ACPS1MAOBKAT6A | |
| SCHEMBL519211 | 0.84 | ALDH1A1 (0.49) | ALDH1A1KMT2ACPS1MAOBRARA | |
| SCHEMBL27655383 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CPS1MAOBRARARARB | |
| SCHEMBL4081642 | 0.83 | ALDH1A1 (1.00) | ALDH1A1KMT2APOLBKDM4EPARP10 | |
| SCHEMBL12493428 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KMT2ACPS1MAOBKAT6A | |
| SCHEMBL6692981 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CPS1MAOBRARARARB | |
| SCHEMBL26109824 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KMT2ACPS1MAOBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836157-A | Oxadiazole derivative and preparation method and application thereof | 星希尔生物科技(上海)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023179366-A1 | OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 星希尔生物科技(上海)有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4061803-A1 | PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 | Eisai R&D Management Co., Ltd. (JP) | 2022-09-28 | — | — | EP | disclosed |
| CN-114981247-A | Piperazine compounds for inhibiting CPS1 | 卫材R&D管理有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021102300-A1 | PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-05-27 | — | — | WO | disclosed |
| EP-2785707-B1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | BAYER IP GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA (US) | 2017-05-25 | — | — | US | disclosed |
| US-9655887-B2 | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-23 | — | — | US | disclosed |
| CN-103517910-B | Morpholine-spirocyclic piperidine amides as modulators of ion channels | 沃泰克斯药物股份有限公司 | 2016-12-14 | — | — | CN | disclosed |
| WO-2012106499-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-1998057910-A2 | CYCLOOXYGENASE-I SELECTIVE INHIBITORS AND THE USE THEREOF AS ANALGESIC, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885KMT2A 2577/4885CPS1 2352/4885 |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | CPS1, CPSF1, CPSF7 | ALDH1A1 1966/4885KMT2A 2040/4885CPS1 1/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | ALDH1A1 1614/4885KMT2A 2425/4885CPS1 2651/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | ALDH1A1 1448/4885KMT2A 4746/4885CPS1 2911/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885KMT2A 2577/4885CPS1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.